Sugi Predict

Sugi Predict / Compounds / SCHEMBL859796

SCHEMBL859796

SCHEMBL859796

CCCCCNCCc1c[nH]cn1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HRH4 Q9H3N8 7/20 0.43
▸ HRH3 Q9Y5N1 7/20 0.43
▸ HTR1A P08908 1/20 0.36
▸ HTR1D P28221 1/20 0.36
▸ HTR1B P28222 1/20 0.36
▸ S1PR2 O95136 3/20 0.34
▸ S1PR1 P21453 3/20 0.34
▸ S1PR3 Q99500 3/20 0.34
▸ MPO P05164 1/20 0.34
▸ S1PR4 O95977 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ KMT2A Q03164 1/20 0.32
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18402529 0.92 HRH4 (0.48) SIGMAR1ALDH1A1TSHRHRH4HRH3
SCHEMBL18871373 0.92 HRH4 (0.44) SIGMAR1ALDH1A1TSHRHRH4HRH3
SCHEMBL7974377 0.92 HRH4 (0.44) SIGMAR1ALDH1A1TSHRHRH4HRH3
SCHEMBL18402586 0.90 HRH4 (0.50) SIGMAR1ALDH1A1TSHRHRH4HRH3
SCHEMBL2897271 0.88 HRH4 (0.39) SIGMAR1ALDH1A1HRH4HRH3HTR1D
SCHEMBL20835000 0.87 HRH4 (0.50) SIGMAR1ALDH1A1TSHRHRH4HRH3
SCHEMBL31364603 0.86 ALDH1A1 (0.31) ALDH1A1CYP1A2CYP2C19
SCHEMBL31364605 0.86 ALDH1A1 (0.31) ALDH1A1CYP1A2CYP2C19
SCHEMBL20834976 0.85 HRH4 (0.44) SIGMAR1ALDH1A1TSHRHRH4HRH3
SCHEMBL1951197 0.83 HRH4 (0.42) ALDH1A1TSHRHRH4HRH3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104023719-B Use of glutaryl histamine for the treatment of respiratory diseases 瓦伦塔有限责任公司 2017-05-24 — — CN claimed
EP-3752838-A1 METHOD FOR DETERMINING TOTAL HISTAMINE DEGRADATION CAPACITY IN BIOLOGICAL SAMPLES Frost Diagnostika GmbH (DE) 2020-12-23 — — EP disclosed
CN-104684569-B Method and agent for treating and preventing diseases caused by (+) RNA-containing virus 制药有限责任公司 2018-03-02 — — CN disclosed
CN-105307650-B Pharmaceutical composition in the form of a tablet and process for its manufacture 瓦伦塔有限责任公司 2017-10-20 — — CN disclosed
WO-2017134430-A1 JAPANESE POLLEN ALLERGEN PEPTIDES FOR PREVENTING OR TREATING ALLERGY CIRCASSIA LIMITED (GB) 2017-08-10 — — WO disclosed
CN-104023719-B Use of glutaryl histamine for the treatment of respiratory diseases 瓦伦塔有限责任公司 2017-05-24 — — CN disclosed
US-20170014505-A1 VACCINE COMPRISING AMB A 1 PEPTIDES FOR USE IN THE TREATMENT OF RAGWEED ALLERGY CIRCASSIA LTD (GB) 2017-01-19 — — US disclosed
EP-3056213-A1 PEPTIDES FOR VACCINE AGAINST BIRCH ALLERGY Circassia Limited (GB) 2016-08-17 — — EP disclosed
US-9347937-B2 Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy CIRCASSIA LIMITED (GB) 2016-05-24 — — US disclosed
EP-2536429-B1 PEPTIDES FOR VACCINES AGAINST BIRCH ALLERGY CIRCASSIA LTD (GB) 2016-02-10 — — EP disclosed
EP-2393830-A1 GRASS PEPTIDES FOR VACCINE Circassia Limited (GB) 2011-12-14 — — EP disclosed
EP-2153841-B1 Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy CIRCASSIA LTD (GB) 2011-12-14 — — EP disclosed
US-20110233059-A1 MICROFLUID SENSOR SENSLAB GESELLSCHAFT ZUR ENTWICKLUNG UND HERSTELLUNG BIOELEKTROCHEMISCHER SENSOREN MBH (DE) 2011-09-29 — — US disclosed
WO-2011098778-A2 PEPTIDES FOR VACCINES AGAINST BIRCH ALLERGY CIRCASSIA LIMITED (GB) 2011-08-18 — — WO disclosed
US-20110200549-A1 Organic Compounds Suitable For Modulating Fragrance Compositions GIVAUDAN SA (CH) 2011-08-18 — — US disclosed
EP-2342180-A2 ORGANIC COMPOUNDS SUITABLE FOR MODULATING FRAGRANCE COMPOSITIONS Givaudan SA (CH) 2011-07-13 — — EP disclosed
WO-2010089554-A1 PEPTIDES FOR VACCINE CIRCASSIA LIMITED (GB) 2010-08-12 — — WO disclosed
WO-2010037244-A2 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2010-04-08 — — WO disclosed
WO-2010018378-A2 RAGWEED PEPTIDES FOR VACCINE CIRCASSIA LIMITED (GB) 2010-02-18 — — WO disclosed
EP-2153841-A1 Vaccine comprising Amb 1 a peptides for use in the treatment of ragweed allergy Circassia Limited (GB) 2010-02-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170014505-A1 VACCINE COMPRISING AMB A 1 PEPTIDES FOR USE IN THE TREATMENT OF RAGWEED ALLERGY NGLY1, MICA, HLA-DRB1 SIGMAR1 4871/4885ALDH1A1 4423/4885TSHR 3329/4885
US-20110200549-A1 Organic Compounds Suitable For Modulating Fragrance Compositions CYP2A6, CYP2B6, CYP2A13 SIGMAR1 1400/4885ALDH1A1 99/4885TSHR 4635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.